Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 6, 1996 - Issue 12
Submit an article Journal homepage
10
Views
3
CrossRef citations to date
0
Altmetric
Research

Section Review Oncologic, Endocrine & Metabolic: Gene therapy for cancer therapeutics

Guadalupe Bilbao Gene Therapy, The University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA
&
David T Curiel Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA; Pulmonary and Critical Care Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA
Pages 1267-1284 | Published online: 29 Feb 2008

References to Primary Literature

  • SEEMAYER TA, CAVANEE WK: Biology of disease: mo•lecular mechanisms of oncogenesis. Lab. Invest. (1989) 60:585-599. This review highlights the different mechanisms involved in the development of the neoplastic process. The timing of oncogenes products expression may be as important in oncogenesis as the level of expression.
  • DURLAND RH, KESSLER DJ, GUNNELL S: Binding of triplex helix-formation oligonucleotides to sites in gene pro-moters. Biochemistry (1991) 30:9246–9255.
  • COONEY M, CZERNUSZEWICZ G, POSTEL EH: Site-spe-cific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science (1988) 241:456–459.
  • EBBINGHAUS SW, GEE JE, RUDU B: Triplex formationInhibits HER-2/neu transcription in vitro. J. Clin. Invest. (1993) 92:2433–2439.
  • CHOO Y, SANCHEZ-GARCIA I, KLUG A: in vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature (1994) 372:642–645.
  • MAYFIELD C, SQUIBB M, MILLER D: Inhibition of nuclear protein binding to the human K-ras promoter by tri-plex-forming oligortucleotides. Biochemistry (1994) 33:3358–3363.
  • MCMANAWAY ME, NECKERS LM, LOKE SL et al.: Tumor-specific inhibition of lymphoma growth by an antis-ense olignucleotide. Lancet (1990) 335:808–811.
  • WATSON PH, PON RT, SHIU RP: Inhibition of c-myc expression by phosphorothioate antisense ollgonu-cleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res. (1991) 51:3996–4000.
  • MUKHOPADHYAY T, TAINSKY M, CAVENDER AC, ROTHJA: Specific inhibition of K-ras expression and tumor-genicity of lung cancer cells by antisense RNA. Cancer Res. (1991) 51:1744–1748.
  • GEORGES RN, MUKHOPADHYAY T, ZHANG Y, YEN N, ROTH JA: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral an-tisenseK-ras constructs. Cancer Res. (1993) 53:1743–1746.
  • ZIIOU P, JAING W, ZHANG Y et al: Antisense to cyclinD1 inhibits growth and reverses the transformed phe-notype of human esophageal cancer cells. Oncogene (1995) 11:571–580.
  • BURFEIND P, CHERNICKY CL, RININSLAND F, ILAN J:Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents inva-sion by rat prostate cancer cells in vivo. Proc. Natl. Acad. Sci. USA (1996) 93:7263–7268.
  • KENNEY NJ, SAEKI T, GOTTARDIS M et al.: Expression of transforming growth factor- a antisense mRNA inhibits the estrogen-induced production of TGF-a and estro-gen-induced proliferation of estrogen-responsive hu-man breast cancer cells. J. Cell Physiol. (1993) 156:497–514.
  • BERTRAM J, KILLIAN M, BRYSCH W, SCHLINGENSIEPEN Kit, KNEBA M: Reduction of erbB-2 gene product in mammary carcinoma cell lines by erbB2 mRNA-s pecific and tyrosine kinase consensus phosphorothioate an-tisense oligonucleotide. Biochem. Biophys. Res. Corn. (1994) 200:661–667.
  • KASHLES 0, YARDEN Y, FISCHER R, ULLRICH A, SCHLESS-INGER J: A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol. Cell Biol. (1991) 11:1454–1463.
  • VASSBOTN FS, ANDERSSON M, WESTERMARK B, HELDIN CH, OSTMAN A: Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol. Cell Biol. (1993) 13:4066–4076.
  • COHEN P, LAMSON G, OKAJIMA T, ROSENFELD RG: Trans-fection of the human insulin-like growth factor binding protein-3 gene into BALB/c fibroblasts inhibits cellular growth. Mol. Endocrinol. (1993) 7:380–386.
  • WINTER G, MILSTEIN C: Man-made antibodies. Nature (1991) 349:293-299. Monoclonal antibodies can now be genetically engineered and endowed with new properties. Gene technology enables antigen-binding fragments to be made by exploiting repertoires of variable domain genes derived from immunised animals and expressed in bacteria.
  • PASTAN I, FITZGERALD D: Recombinant inununotoxinsfor cancer treatment. Science (1991) 254:1173–1177.
  • HUSTON JS, LEVINSON D, MUDGETT-HUNTER M et al.:Protein engineering of antibody binding sites: recovery of specific activity in an anidigoxin single-chain Fv analogue produced inEscbericbia coll. Proc. Natl, Acad. Sci. USA (1988) 85:5879–5883.
  • CHEN SY, BAGLEY J, MARASCO WA: Intracelhilnr antibodies as a new class of therapeutic molecules for gene therapy. Hum. Gene Ther. (1994) 5:595-601. This paper describes single chain antibodies (intrabodies) as a new class of active molecules that may be usful for the gene therapy of acquired immunodeficiency virus and other diseases.
  • MARASCO WA: Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology (1995) 1:1-19. This review provides a comprehensive update on the use of intra-cellular antibodies, with the focus on gene therapy for HIV and cancer.
  • DESHANE J, LOECHEL F, CONRY RM et al.: Intracellular single-chain antibody directed against erbB2 down regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB-2 overexpressing can-cer cell lines. Gene Ther. (1994) 1: 332–337. An intracelluar single chain antibody, targeted to the endoplasmic reticulum was directed against the erbB-2 oncogene.
  • DESHANE J, SIEGAL GP, ALVAREZ RD et al.: Targeted tumor cell killing via an intracellular antibody directed against the erbB-2. J. Clin. Invest. (1995) 96:2980–2989.
  • DESHANE J, GRIM J, LOECHEL F et al.: Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Then (1996). In press.
  • BARNES NB, DESHANE JS, SIEGAL GP, ALVAREZ RD, CURIEL DT: Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell c_hemosensitivity. Clin. Cancer Res. (1996) 2:1089-1095. This paper shows that down regulation of erbB-2 oncoprotein by single chain antibody results in enhanced tumor cell chemosensitiv-ity.
  • FUJIWARA T, GRIMM EA, MUKHOPADHYAY T et al.: A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by Inducing apoptosis. Cancer Res. (1993) 53:4129-4133. This paper demostrates that direct administration of a retroviral vector-expressing wild-type p53 may inhibit local growth of human lung cancer cells that are deficient in wild-type p53.
  • CASEY G, LO-IISL'ETI M, LOPEZ ME, VOGELSTEIN B, STAN-BRIDGE EJ: Growth supression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene (1991) 6: 1791-1797.
  • WANG NP, TO H, LEE WH, LEE EY: Tumor supressor activity of Rb and p53 in human breast carcinoma cells. Oncogene (1993) 8:279–288.
  • RUNNEBAUM 113, KREIENBERG R: p53 Trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy. Hybridoma (1995) 14:153–157.
  • XU HJ, ZHOU Y, SEIGNE J et al.: Enhanced tumor supres- sor gene therapy via replication deficient adenovirus vectors expressing an N-terminal truncated retinoblas-toma -protein. Cancer Res. (1996) 56:2245-2249. This paper presents the preclinical studies that demostrated that treatment of human non-small cell lung carcinoma and bladder carcinoma cells by recombinant adenovirus vector expressing the N-terminal truncated retinoblastoma protein completely suppressed the tumourigenicity of the treated tumour cells in nude mice.
  • HOLT JT, THOMPSON ME, SZABO C et at: Growth retar- dation and tumor inhibition by BRCA-1. Nature Genet, (1996) 12:298-302. This paper highlights the importance of the BRCA-1 gene in sporadic breast and ovarian cancer. Here, they show that retroviral transfer of the wild-type BRCA1 gene inhibits growth in vitro and in vivo of a panel of breast and ovarian cell lines.
  • JENSEN RA, THOMPSON ME, JETTON TL et al.: BRCA1 is secreted and exhibits properties of a granin. Nature Genet. (1996) 12: 303–308.
  • EALOVEGA MW, MCGINNIS PK, SUMANTRAN VN, CLARKE MF, WICHA MS: Bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res. (1996) 56:1965-1969. This paper show that infection with replicative-deficient adenoviral vector expressing Bcl-xs into MCF-7 human breast cancer cells induces apoptosis in vitro. Intratumoural injection of this same vector demonstrated a 50% reduction in size in vivo.
  • CLARKE MF, APEL IJ, BENEDICT MA et al.: A recombinantbcl-xs adenovirus selectively induces apoptosis in can-cer cells but not in normal bone marrow cells. Proc. Nati, Acad. Sci. USA (1995) 92:11024–11028.
  • BARGOU RC, WAGENER C, BOMMERT K et al.: Overeatpression of the death-promoting gene bax-aipba which Is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice.]. Clin. Invest. (1996) 97:2651-2659. In this paper the authors compare the expression pattern of members of the bc1-2 family in normal and breast cancer tissue samples. No marked difference with regard to bcl-2 and bc1-xl expression was observed between them. However, bax-alpha, which promotes apoptosis, is expressed in high amounts in normal breast epithelium, whereas only weak or no expression could be detected in cancer samples.
  • WIGLER M, SLLVERSTEIN S, LEE L etTransfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell (1977) 11:223–232.
  • ELTON GB, FURMAN PA, FYFE JA et al.:Selectivity of action of an antiherpetic agent, 9-(2-dyroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. USA (1977) 74:5716–5720.
  • FURMAN PA, MCGUIRT PV, KELLER PM, FYFE JA, ELION GB: Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with her-pes virus genetic information. Virology (1980) 102:420–430.
  • CULVER KW, RAM Z, WALLBRIDGE S et al.: In vivo genetransfer with retroviral vector-producer cells for treat-ment of experimental brain tumors. Science (1992) 256:1550–1552.
  • FREEMAN SM, ABBOUD CN, WHARTENBY KA et al.: The'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. (7993) 53:5274–5283.
  • BI WL, PARYSEK LM, WARNICK R, STAMBROOK PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV TK retroviral gene therapy. Hum. Gene Ther. (1993) 4:725–731.
  • CARUSO M, PANIS Y, GAGANDEEP S et al.: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA (1993) 90:7024–7028.
  • CONSALVO M, MULLEN CA, MODESTI A et al.: 5-Fluorcy-tosine-induced eradication of murine adenocarci-nomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol. (1995) 154:5302–5312.
  • GAGANDEEP S, BREW R, GREEN B et al.: Prodrug-acti-vated gene therapy: involvement of an immunological component in the 'bystander' effect. Cancer Gene Ther. (1996) 3:83–88.
  • SMYTHE WR, HWANG HC, AMIN KM etal.: Use of recom-binant adenovirus to transfer the herpes simplex virus tymidine kinase (HSV-TK) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. (1994) 54:2055–2059.
  • HWANG HC, SMYTHE WR, ELSHAMI AA et al.: Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am. J. Resp. Cell Mol. Biol. (1995) 13:7–16.
  • BONNEKOH B, GREENHALGH DA, BUNDMAN DS et al.:Inhibition of melanoma growth by adenoviral-medi-ated HSV thymidine kinase gene transfer in vivo. J. Invest. Dermatol. (1995) 104:313–317.
  • O'MALLEY BW, Jr., CHEN SH, SCHWARTZ MR, WOO SL: Adenovirus-mediated gene therapy for human head and neck squamous cell can in a nude mouse modeL Cancer Res. (1995) 55:1080-1085. This paper underlines that adenovirus-mediated gene transfer as a clinically effective in vivo treatment of human squamous cell cancer can be achieved using adenovirus-mediated gene therapy.
  • SACCO MG, MANGIARINI L, VILLA A et al.: Local regression of breast tumors following intramammary ganci-clovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Gene Ther. (1995) 2:493–497.
  • RAM Z, WALLBRIDGE S, SHAWKER T etal.: The effect of thymidine kinase transduction and gancklovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurgery (1994) 81:256–260.
  • IZQUIERDO M, CORTES M, DE FELIPE P et al: Long-term rat survival after malignant brain tumor regression by retroviral gene therapy. Gene Ther. (1995) 2:66–69.
  • COLOMBO BM, BENEDETTI S, OTTOLENGHI S et al.: The'bystander effect': association of U-87 cell death with gancidovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. (1995) 6:763–772.
  • HIRSCHOWITZ EA, OHWADA A, PASCAL WR, RUSSI TH, CRYSTAL RG : In vivo adenovirus-mediated gene transfer of Escbericia coil cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensi-tivity to 5-fluorocytosine. Hum Gene Ther. (1995) 6: 1055–1063. Observations in this paper suggest that adenovirus-mediated gene transfer of E. colt cytosine deaminase gene and concomitant admini-stration of 5FC may have potential as a strategy for local control of the growth of tumor cells susceptible to 5FU.
  • PATTERSON AV, ZHANG H, MOGHADDAM A et al.: In-creased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer (1995) 72:669–675.
  • DOUGLAS JT, CURIEL DT: Targeted gene therapy. Tumor Targeting (1995) 1:67-84. This review overviews major considerations for gene therapy strate-gies in the context of targeting the therapeutic gene(s) selectively into the tumor.
  • H1LKENS J, BUDS F, HILGERS J etal.: Monoclonal antibod-ies against human milk-fat globule membranes detect-ing differentiation antigens of the mammary gland and Its tumors. Int. J. Cancer (1984) 34:197–206.
  • BURCHELL J, GENDLER S, TAYLOR-PAPADIMITRIOU J etal.: Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. (1987) 47:5476–5482.
  • TAGLIABUE E, CENTIS F, CAMPIGLIO M et al.: Selection ofmonoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibi-tion of cells with HER2/neu gene amplification Int. J. Cancer (1991) 47:933–937.
  • DREB1N JA, LINK VC, GREEN MI: Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene (1988) 2:387–394.
  • HAN X, KASAHARA N, KAN YW: Ligand-directed retrovital targeting of human breast cancer cells. Proc. Natl. Acad. Sci. USA (1995) 92:9747-9751. The authors explored the feasibility of designing retroviral vectors that can target human breast cancer with characteristic receptors via ligand-receptor interaction. The ecotropic Moloney murine leukemia virus envelope was modified by insertion of sequences encoding human heregulin.
  • CRISTIANO RJ, CURIEL DT: Strategies to accomplish gene delivery via the receptor mediated endocytosis path-way. Cancer Gene Ther. (1996). In press.
  • FOMINAYA J, WELS W: Target cell-specific DNA transfer mediated by a chimeric multidomain protein. J. Biol. Chem. (1996). In press. This paper is based on the muhidomain structure of the bacterial Pseudomonas exotoxin A; a recombinant fusion protein was con-structed which serves as a target cell-specific carrier for the transfer of DNA via receptor-mediated endocytosis.
  • IIARRIS JD, GUTIERREZ AA, HURST IIC, SIKORA K, LEMOINE NR: Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. (1995) 1:170–175.
  • MANOME Y, ABE M, HAGEN MF, FINE HA, KUFE DW: Enhancer sequences of the DF3 gene regulate expres-sion of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. (1994) 54: 5408–5413. Enhanced sensitivity of breast cancer cells to ganciclovir was achieved via transcriptional regulation of HSV-TK expression with an enhancer sequence from the breast specific DF3 promoter. Evidence for a bystander effect was also shown.
  • CHEN L, CHEN D, MANOME Y et al.: Breast cancer selective gene expression and therapy mediated by recom-binant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. (1995) 96:2775-2782. This paper demonstrates that utilisation of the DF3 promoter in an adenoviral vector can confer selective expression of heterologous genes in breast cancer cells in vitro and in vivo.
  • DOPPLER W, VILLUNGER A, JENNEWEIN P et al.: Lacto- genic hormone and cell type-specific control of whey acidic protein gene promoter in transfected mouse cells. Mol. Endocrinol. (1991) 5: 16 24–1 63 2.
  • BANYA EM, ROSEN JM: Tissue-specific, high-level ex-pression of the rat whey acidic protein gene in trans-genic mice. Nucleic Acid Res. (1990) 18:2977–2985.
  • WANG Y, O'MALLEY BW, Jr., TSAI SY, O'MALLEY BW: A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA (1994) 91:8180–8184.
  • SORRENTINO BP, BRANDT SJ, BODINE D etal.: Selectionof drug-resistant bone marrow cell in vivo after retrovi-ral transfer of human MDR1. Science (1992) 257:99–103.
  • ALLAY JA, DUMENCO LL, KOC ON, LIU L, GERSON SL: Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood (1995) 85:3342–3351.
  • KOC ON, ALLAY JA, LEE K etal.: Transfer of drug resis-tance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin. Oncol. (1996) 23:46–65.
  • DOROSHOW JH, METZ MZ, MATSUMOTO L et al.: Transduction of NM 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase Pi produces broad-range multidrug resistance. Cancer Res, (1995) 55:4073–4078.
  • BIENZLE D, ABRAMS-OGG AC, KRUTH SA et al.: Genetransfer into hematopoietic stem cells: long-term main-tenance of in vitro activated progenitors without mar-row ablation. Proc. Natl. Acad. Sci. USA (1994) 91:350–354.
  • OTTGEN HF: The history of cancer immunotherapy. Biological Therapy of Cancer, Principles and Practice. De Vita VT, Heiman S, Rosenberg SA (Eds.), JB Lippencott, USA (1991)
  • SAHIN U, TURECI 0, SCHMITT II etal.: Human neoplasmselicit multiple specific immune responses in the autolo-gous host. Proc. Natl. Acad. Sci. USA (1995) 92:11810–11813.
  • PARDOLL DM Tumour antigens: a new look for the1990s. Nature (1994) 369:357–358.
  • TANAKA K, ISSELBACHER KJ, KHOURY G, JAY G: Reversal of oncogensis by the expression of a major histocom-patibility complex class I gene. Science (1985) 228:26–30.
  • TANAKA K, GORELIK E, WATANBE M, HOZUMI N, JAY G: Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol. Cell Biol. (1988) 8:1857–1861.
  • CHEN PW, ANANTHASWAMY FIN: Rejection of K1735murine melanoma in syngeneic hosts requires expres-sion of MHC class I antigens and either class II antigens or IL-2.J. Immunol. (1993) 151:244–255.
  • GIMMI CD, FREEMAN GJ, BRII3BEN JG, GRAY G, NADLERLM: Human T cell anergy is induced by antigen presen-tation in the absence of B7 costirnulation. Proc. Natl. Acad. Sci. USA (1993) 90:6586–6590.
  • FEARON ER, PARDOLL DM, ITAYA T etal.: Interleukin-2production by tumor cells bypasses T helper function In the generation of an antitumor response. Cell (1990) 60:397–403.
  • CAVALLO F, DI PIERRO F, GIOVARELLI M etal.: Protectiveand curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. (1993) 53:5067–5070.
  • TEPPER RI, PATTENGALE PK, LEDER P: Murine inter-leukin-4 displays potent anti-tumor activity in vivo. Cell (1989) 57:503–512.
  • BLANKENSTEIN T, QIN Z, UBERLA K: Tumor supression after tumor cell-targeted tumor necrosis factor-a gene transfer. J. Exp. Med. (1991) 173:1047–1052.
  • LOPEZ-CEPERO M, GARCIA-SANZ JA, HERBERT L et al.: Soluble and membrane-bound TNF-alpha are involved In the cytotoxic activity of B cells from tumor-bearing mice against tumor targets. J. Immunol. (1994) 152:3333–3341.
  • ALLIONE A, CONSALVO M, NANNI P et al.: Immunizingand curative potential of replicating and non-replicat-ing murine mammary adenocarcinoma cells engi-neered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage col-ony-stimulating factor, and '-interferon gene or ad-mixed with conventional adjuvants. Cancer Res. (1994) 54:6022–6026.
  • FENTON RG, TAUB DD, KWAK LW: Cytotoldc T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J. Nail. Cancer Ins,. (1993) 85:1294–1302
  • BARND DL, LAN MS, METZGAR RS, FINN 0J: Specific,major histocompatibllity complex-unrestricted recog-nition of tumor-associated mucins by hyman cytotoxk T cells. Proc. Natl. Acad. Sci. USA (1989) 86:7159–7163.
  • LIVINGSTON PO, WONG GYC, ADLURI S et at: Improvedsurvival in stage III melanoma patients with GM2 anti-bodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. (1994) 12:1036–1044.
  • BERGERS JJ, OTTER WD, DULLENS HF et al.: Effect of immunomodulators on specific tumor immunity in-duced by liposome-encapsulated tumor associated an-tigens. Int.]. Cancer (1994) 56:721–726.
  • KANTOR J, IRVINE K, ABRAMS S et al.: Antitumor activityand immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. (1992) 84:1084–1091.
  • UN KY, GUARNIERI FG, STAVELEY-O'CARROLL KF et al.:
  • •Treatment of established tumors with a novel vaccine that enchance major histocompatibility class 11 presen-tation of tumor antigen. Cancer Res. (1996) 56:21-26. In this paper this group demonstrate that the modifications that reroute a cytosolic tumour antigen to the endosomal/lysosomal compartment can profoundly improve the in vivo therapeutic po-tency of recombinant vaccines.
  • WOLFF JA, LUDTKE JJ, ACSADI G, WILLIAMS P, JANI
  • •Long-term expression of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. (1992) 1:363-369. This paper describes direct gene transfer by intramuscular injection of naked plasmid DNA encoding a foreign gene. DNA-based immu-nisation may be of value for basic immunological research an vaccine development.
  • MCDONNELL WM, ASKARI FK: Molecular medicine: DNA vaccines. New Engl. J. Med. (1996) 334:42–45.
  • CONRY RM, LOBUGLIO AF, LOECHEL F et al.: A carcinoembryonic antigen polynucleotide vaccine has in vivoantitumor activity. Gene Ther. (1995) 2:59-65. A plasmid encoding the cDNA for CEA functioned as a polynu-cleotide vaccine to elicit humoral and cellular immune response and protected against syngenic CEA-expressing colon cancer cells.
  • CONRY RM, LOBUGLIO AF, CURIEL DT: Polynucleoticle-mediated immunization therapy of cancer. Semin. On-to!. (1996) 23:135–147.
  • WANG B, MERVA M, DANG K et al.: Immunization by direct DNA inoculation induces rejection of tumor cell challenge. Hum. Gene Ther. (1995) 6:407–418.
  • SPOONER RA, DEONARAIN MP, EPENETOS AA: DNA vacciliation for cancer treatment_ Gene Ther. (1995) 2:173-180. Expression of DNA encoding fragments of tumour-specific proteins as neo-antigens or surrogate antigens in a novel context may be a means of breaking immunological tolerance, and may lead to the generation of tumour-specific immune responses.
  • CONRY RM, LOBUGLIO AF, WRIGHT M et al.: Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. (1995) 55:1397-1400. This paper reports on the feasibility of using mRNA transcripts for polynucleotide vaccination strategies.
  • MARTINON F, KRISHNAN S, LENZEN G etal.: Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Fur J. Immunol. (1993) 23:1719–1722.
  • QUI P, ZIEGELHOFFER P, SUN J, YANG NS: Gene gun delivery of mRNA in situ results in efficient transgeneexpression and genetic immunization. Gene Ther. (1996) 3:262-268. This paper describes an in situ transgene expression by Accell particle-mediated gene transfer.
  • JOHANNING FW, CONRY RM, LOBUGLIO AF et al.: A sindbis virus mRNA polynucleotide vector achieves prolonged and high-level heterologous gene expres-sion in vivo. Nucl. Acids Res. (1995) 23:1495–1501.
  • XIONG C, LEVIS R, SIIEN P et al.: Sindbis virus: an efficient, broad host range vector for gene expression In animal cells. Science (1989) 243:1188–1191.
  • HAHN CS, HAHN YS, BRACIALE TJ, RICE CM: Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc. Natl. Acad. Sci. USA (1992) 89:2679–2683.
  • MORRIS DJ, BAILEY AS, COOPER RJ et al.: Polymerase chain reaction for rapid detection of ocular adenovirus infection. J. Med. Virol. (1995) 46:126–132.
  • SACI IS AB: Messenger RNA degradation in eukaryotes. Cell (1993) 74:413–421.
  • BEELMAN CA, PARKER R: Degradation of mRNA in eu-karyotes. Cell (1995) 81:179–183.
  • AURUP H, SIEBERT A, BENSELER F, WILLIAMS D, ECKSTEIN F: Translation of a 2'-modified mRNA in vitro and in vivo. Nucl. Acids Res. (1994) 22:23232–23236.
  • HEIDENREICH 0, PIEKEN W, ECKSTEIN F: Chemically modified RNA: approaches and applications. FASEB J. (1993) 7:90–96.
  • SIVANANDHAM M, SCOGGIN SD, TANAKA N, WALLACK MK: Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2 gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol. Immunother. (1994) 38259–264.
  • BERTH1ER-VERGNES 0, PORTOUKALIAN J, LEFTHERIOTIS E, DORE J: Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patient immunized with vaccinia virus melanoma lysates. Cancer Res. (1994) 54:2433–2439.
  • HEIKE M, BLACHERE ME, WOLFEL T et al.: Membranes activate tumor- and virus-specific precursor cytotoxic T lymphocytes in vivo and stimulate tumor-specific T lymphocytes in vitro: implications for vaccination. J. Immunother. Tumor Immunol. (1994) 15:165–174.
  • GUO Y, WU M, CHEN H et al: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science (1994) 263:518–520.
  • FRIEDMANN T: Genetically modified tumor-infiltrating lymphocytes for cancer therapy. Cancer Cells (1991) 3:271–274.
  • ROSENBERG SA, ABERSOLD P, CORNETTA K et al.: Gene transfer into humans: ireununotherapy of patients with advanced melanoma, using tumor-infiltrating lympho-cytes modified by retroviral gene transduction. New Engl. J. Med. (1990) 323:570–578.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.